Oncotarget

Reviews:

Homeodomain-interacting protein kinase 2 (HIPK2): a promising target for anti-cancer therapies

Yuanyuan Feng, Lihong Zhou, Xiaoting Sun and Qi Li _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:20452-20461. https://doi.org/10.18632/oncotarget.14723

Metrics: PDF 914 views  |   HTML 1406 views  |   ?  


Abstract

Yuanyuan Feng1,*, Lihong Zhou1,*, Xiaoting Sun1 and Qi Li1

1 Department of Medical Oncology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China

* These authors have contributed in equal measure as the first author

Correspondence to:

Qi Li, email:

Keywords: HIPK2; cancer; p53; apoptosis; angiogenesis

Received: September 02, 2016 Accepted: January 04, 2017 Published: January 18, 2017

Abstract

The HIPK2 (serine/threonine homeodomain-interacting protein kinase 2) is a “caretaker” gene, its inactivation increases tumorigenicity while its activation inhibits tumor growth. This report reviews the anti-tumorigenic mechanisms of HIPK2, which include promotion of apoptosis, inhibition of angiogenesis in hypoxia, prevention of tumor invasion/metastasis and attenuation of multidrug resistance in cancer. Additionally, we summarize conditions or factors that may increase HIPK2 activity.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 14723